Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF. Ellingson BM, et al. Neuro Oncol. 2018 Aug 2;20(9):1240-1250. doi: 10.1093/neuonc/noy053. Neuro Oncol. 2018. PMID: 29660006 Free PMC article. Clinical Trial.
Accelerated progression of IDH mutant glioma after first recurrence.
Miller JJ, Loebel F, Juratli TA, Tummala SS, Williams EA, Batchelor TT, Arrillaga-Romany I, Cahill DP. Miller JJ, et al. Neuro Oncol. 2019 May 6;21(5):669-677. doi: 10.1093/neuonc/noz016. Neuro Oncol. 2019. PMID: 30668823 Free PMC article.
Performance of a Hospital Pathway for Patients With a New Single Brain Mass.
Arrillaga-Romany I, Curry WT Jr, Jordan JT, Cahill DP, Nahed BV, Martuza RL, Loeffler JS, Järhult SJ, Muzikansky A, Cohen AB, Singhal AB, Goldstein JN, Batchelor TT. Arrillaga-Romany I, et al. J Oncol Pract. 2019 Mar;15(3):e211-e218. doi: 10.1200/JOP.17.00098. Epub 2019 Jan 25. J Oncol Pract. 2019. PMID: 30681891
Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma.
Chi AS, Cahill DP, Reardon DA, Wen PY, Mikkelsen T, Peereboom DM, Wong ET, Gerstner ER, Dietrich J, Plotkin SR, Norden AD, Lee EQ, Nayak L, Tanaka S, Wakimoto H, Lelic N, Koerner MV, Klofas LK, Bertalan MS, Arrillaga-Romany IC, Betensky RA, Curry WT, Borger DR, Balaj L, Kitchen RR, Chakrabortty SK, Valentino MD, Skog J, Breakefield XO, Iafrate AJ, Batchelor TT. Chi AS, et al. JCO Precis Oncol. 2020 Jun 8;4:PO.19.00295. doi: 10.1200/PO.19.00295. eCollection 2020. JCO Precis Oncol. 2020. PMID: 32923886 Free PMC article.
Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas.
Brastianos PK, Kim AE, Giobbie-Hurder A, Lee EQ, Wang N, Eichler AF, Chukwueke U, Forst DA, Arrillaga-Romany IC, Dietrich J, Corbin Z, Moliterno J, Baehring J, White M, Lou KW, Larson J, de Sauvage MA, Evancic K, Mora J, Nayyar N, Loeffler J, Oh K, Shih HA, Curry WT, Cahill DP, Barker FG, Gerstner ER, Santagata S. Brastianos PK, et al. Nat Commun. 2022 Mar 14;13(1):1325. doi: 10.1038/s41467-022-29052-7. Nat Commun. 2022. PMID: 35289329 Free PMC article. Clinical Trial.
47 results